Cookies help us deliver our services. By using our services, you agree to our use of cookies. More information

Search by property

From Bioblast

This page provides a simple browsing interface for finding entities described by a property and a named value. Other available search interfaces include the page property search, and the ask query builder.

Search by property

A list of all pages that have property "Has abstract" with value "Glucocorticoids are used in the therapy of acute lymphoid leukemia (ALL) as well as and other lymphoid malignancies. An initial insufficient response to glucocorticoids has been shown to be an important prognostic marker for a bad outcome. 2-Deoxy-glucose (2-DG) is a glucose analog which is not metabolized and sensitizes ALL-cells to non-toxic doses of glucocorticoids and resistant cells to glucocorticoids. However, the underlying molecular mechanism of glucocorticoid-induced cell death and the synergism with 2-DG remains poorly understood. Prior work has shown a downregulation of the mitochondrial glutamate/H+-symporter (SLC25A22) and the mitochondrial dicarboxylate carrier (SLC25A10) in response to treatment with the glucocorticoid dexamethasone (DEX). Here I analyze the microsomal fraction of treated leukemic cells with a proteomic approach to further elucidate the mechanism. I show that treatment with 2-DG alone and in combination with DEX leads to increased expression of NMT-1, which has been implicated in the induction of apoptosis, and a reduction of HADH, an enzyme of beta-oxidation. I also show that inhibition of glycolysis by 2-DG is associated with downregulation of VDAC1. No synergistic effect with DEX can be shown. The mechanism of synergy between 2-DG and glucocorticoids remains unclear.". Since there have been only a few results, also nearby values are displayed.

Showing below up to 2 results starting with #1.

View (previous 50 | next 50) (20 | 50 | 100 | 250 | 500)


    

List of results

    • Aubin 2019 Thesis  + (Glucocorticoids are used in the therapy ofGlucocorticoids are used in the therapy of acute lymphoid leukemia (ALL) as well as and other lymphoid malignancies. An initial insufficient response to glucocorticoids has been shown to be an important prognostic marker for a bad outcome.</br></br>2-Deoxy-glucose (2-DG) is a glucose analog which is not metabolized and sensitizes ALL-cells to non-toxic doses of glucocorticoids and resistant cells to glucocorticoids. However, the underlying molecular mechanism of glucocorticoid-induced cell death and the synergism with 2-DG remains poorly understood.</br></br>Prior work has shown a downregulation of the mitochondrial glutamate/H+-symporter (SLC25A22) and the mitochondrial dicarboxylate carrier (SLC25A10) in response to treatment with the glucocorticoid dexamethasone (DEX). Here I analyze the microsomal fraction of treated leukemic cells with a proteomic approach to further elucidate the mechanism.</br></br>I show that treatment with 2-DG alone and in combination with DEX leads to increased expression of NMT-1, which has been implicated in the induction of apoptosis, and a reduction of HADH, an enzyme of beta-oxidation.</br></br>I also show that inhibition of glycolysis by 2-DG is associated with downregulation of VDAC1. No synergistic effect with DEX can be shown.</br></br>The mechanism of synergy between 2-DG and glucocorticoids remains unclear. 2-DG and glucocorticoids remains unclear.)